A practical reference on nasal drops: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| 结构类别 | 线性合成七肽 | 无环化结构，不含二硫键 |
| 氨基酸序列 | Met-Glu-His-Phe-Pro-Gly-Pro | N 端为甲硫氨酸 |
| 分子量 | 约 814 Da | 游离碱形式的计算值 |
| 外观 | 白色至类白色粉末 | 具吸湿性 |
| 溶解性 | 易溶于水 | 亦可溶于甲醇等极性溶剂 |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
=== EC 1.14.99 Miscellaneous === EC 1.14.99.1: prostaglandin-endoperoxide synthase EC 1.14.99.2: kynurenine 7,8-hydroxylase EC 1.14.99.3: Now EC 1.14.14.18, heme oxygenase (biliverdin-producing) EC 1.14.99.4: progesterone monooxygenase EC 1.14.99.5: Now EC 1.14.19.1, stearoyl-CoA 9-desaturase EC 1.14.99.6: Now EC 1.14.19.2, acyl-[acyl-carrier-protein] desaturase EC 1.14.99.7: Transferred to EC 1.14.13.132, squalene monooxygenase EC 1.14.99.8: Now included with EC 1.14.14.1 unspecific monooxygenase EC 1.14.99.9: Now classified as EC 1.14.14.19, steroid 17α-monooxygenase EC 1.14.99.10: Now EC 1.14.14.16, steroid 21-monooxygenase EC 1.14.99.11: estradiol 6β-monooxygenase EC 1.14.99.12: 4-androstene-3,17-dione monooxygenase EC 1.14.99.13: Now EC 1.14.13.23, 3-hydroxybenzoate 4-monooxygenase EC 1.14.99.14: Now EC 1.14.14.197, progesterone 11α-monooxygenase EC 1.14.99.15: 4-methoxybenzoate monooxygenase (O-demethylating) EC 1.14.99.16: Now EC 1.14.13.72, methylsterol monooxygenase EC 1.14.99.17: Now EC 1.14.16.5, glyceryl-ether monooxygenase EC 1.14.99.18: deleted EC 1.14.99.19: Now classified as EC 1.14.19.77, plasmanylethanolamine desaturase EC 1.14.99.20: phylloquinone monooxygenase (2,3-epoxidizing) EC 1.14.99.21: Latia-luciferin monooxygenase (demethylating) EC 1.14.99.22: ecdysone 20-monooxygenase EC 1.14.99.23: 3-hydroxybenzoate 2-monooxygenase EC 1.14.99.24: steroid 9α-monooxygenase EC 1.14.99.25: Now EC 1.14.19.3, linoleoyl-CoA desaturase EC 1.14.99.26: 2-hydroxypyridine 5-monooxygenase EC 1.14.99.27: Now classified as EC 1.17.3.4, juglone 3-monooxygenase EC 1.14.99.28: Now EC 1.14.14.84, linalool 8-monooxygenase EC 1.14.99.29: deoxyhypusine monooxygenase EC 1.14.99.30: Now EC 1.3.5.6, 9,9′-dicis-ζ-carotene desaturase. EC 1.14.99.31: Now classified as EC 1.14.19.24, myristoyl-CoA 11-(E) desaturase EC 1.14.99.32: Now classified as EC 1.14.19.5, acyl-CoA 11-(Z)-desaturase EC 1.14.99.33: Now EC 1.14.19.39, acyl-lipid Δ12-acetylenase EC 1.14.99.34: monoprenyl isoflavone epoxidase EC 1.14.99.35: thiophene-2-carbonyl-CoA monooxygenase EC 1.14.99.36: Now classified as EC 1.13.11.63, β-carotene 15,15′-dioxygenase EC 1.14.99.37: Now EC 1.14.14.176, taxadiene 5α-hydroxylase EC 1.14.99.38: cholesterol 25-hydroxylase EC 1.14.99.39: ammonia monooxygenase EC 1.14.99.40: Now EC 1.13.11.79, 5,6-dimethylbenzimidazole synthase EC 1.14.99.41: Now EC 1.13.11.75, all-trans-8′-apo-β-carotenal 15,15′-oxygenase EC 1.14.99.42: Now EC 1.13.11.84, crocetin dialdehyde synthase EC 1.14.99.43: Now EC 1.14.14.134, β-amyrin 24-hydroxylase EC 1.14.99.44: diapolycopene oxygenase EC 1.14.99.45: Now EC 1.14.14.158, carotene ε-monooxygenase EC 1.14.99.46: pyrimidine oxygenase EC 1.14.99.47: (+)-larreatricin hydroxylase EC 1.14.99.48: heme oxygenase (staphylobilin-producing) EC 1.14.99.49: Now EC 1.14.15.31, 2-hydroxy-5-methyl-1-naphthoate 7-hydroxylase EC 1.14.99.50: γ-glutamyl hercynylcysteine S-oxide synthase EC 1.14.99.51: hercynylcysteine S-oxide synthase EC 1.14.99.52: L-cysteinyl-L-histidinylsulfoxide synthase EC 1.14.99.53: lytic chitin monooxygenase EC 1.14.99.54: lytic cellulose monooxygenase (C1-hydroxylating) EC 1.14.99.55: lytic starch monooxygenase EC 1.14.99.56: lytic cellulose monooxygenase (C4-dehydrogenating) EC 1.14.99.57: heme oxygenase (mycobilin-producing) EC 1.14.99.58: heme oxygenase (biliverdin-IX-β and δ-forming) EC 1.14.99.59: tryptamine 4-monooxygenase EC 1.14.99.60: 3-demethoxyubiquinol 3-hydroxylase EC 1.14.99.61: cyclooctat-9-en-7-ol 5-monooxygenase EC 1.14.99.62: cyclooctatin synthase EC 1.14.99.63: β-carotene 4-ketolase EC 1.14.99.64: zeaxanthin 4-ketolase EC 1.14.99.65: 4-amino-L-phenylalanyl-[CmlP-peptidyl-carrier-protein] 3-hydroxylase EC 1.14.99.66: [histone H3]-N6,N6-dimethyl-L-lysine4 FAD-dependent demethylase EC 1.14.99.67: α-N-dichloroacetyl-p-aminophenylserinol N-oxygenase EC 1.14.99.68: 4-aminobenzoate N-oxygenase EC 1.14.99.69: tRNA 2-(methylsulfanyl)-N6-isopentenyladenosine37 hydroxylase
=== Apical delta === Apical delta refers to the branching pattern of small accessory canals and minor foramina seen at the tip or apex of some tooth roots. The pattern is said to be reminiscent of a river delta when sectioned and viewed using a microscope. Because the anatomy of this area is very small and complex with several portals of entry to the root canal i.e. more than one apical foramen.
Instead, the ionic current from an action potential at one node of Ranvier provokes another action potential at the next node; this apparent "hopping" of the action potential from node to node is known as saltatory conduction. Although the mechanism of saltatory conduction was suggested in 1925 by Ralph Lillie, the first experimental evidence for saltatory conduction came from Ichiji Tasaki and Taiji Takeuchi and from Andrew Huxley and Robert Stämpfli. By contrast, in unmyelinated axons, the action potential provokes another in the membrane immediately adjacent, and moves continuously down the axon like a wave.
Sources: en.wikipedia.org
OPD (o-phenylenediamine dihydrochloride) turns amber to detect HRP (horseradish peroxidase), which is often used to as a conjugated protein. TMB (3,3',5,5'-tetramethylbenzidine) turns blue when detecting HRP and turns yellow after the addition of sulfuric or phosphoric acid. ABTS (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) turns green when detecting HRP. PNPP (p-Nitrophenyl Phosphate, Disodium Salt) turns yellow when detecting alkaline phosphatase.
== Early life and career == Natalie Paige Cochran (née Jessup; born November 1980) was born in Raleigh County, West Virginia. She pursued a career in pharmacy and married Michael Brandon Cochran in the early 2000s. The couple had two children and ran a contracting business during the 2010s, which later became central to her legal troubles.
=== Multinational corporations === The OECD Guidelines for Multinational Enterprises are a set of legally non-binding guidelines attached as an annexe to the OECD Declaration on International Investment and Multinational Enterprises. They are recommendations providing principles and standards for responsible business conduct for multinational corporations operating in or from countries adhering to the Declaration.
Sources: en.wikipedia.org
不存在。它是依据 ACTH 的一段序列人工设计的分子，天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号，而非天然物质名。
Semax 对应 ACTH 第 4 至第 10 位的片段，并在两端做了替换与延长，使其不再具备促肾上腺皮质激素的典型内分泌活性。这一改动同时改变了它在体内的稳定性与分布特征。
俄罗斯将其列为处方药物，需要医生开具处方。多数其他国家把它当作研究化合物，不能作为药品销售或宣称疗效。具体合法性取决于当地法规。
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.